Ebola Virus Disease (EVD): Understanding the Deadly Viral Infection
Ebola Virus Disease (EVD) is one of the world’s most dangerous infectious diseases, known for causing severe hemorrhagic fever and high mortality rates. First identified in 1976 near the Ebola River in the Democratic Republic of Congo, the disease has caused multiple outbreaks across Africa and remains a major global public health concern.
EVD is caused by viruses belonging to the genus Ebolavirus, with the Zaire ebolavirus species being the deadliest and most commonly associated with large outbreaks. The disease spreads rapidly through direct contact with infected body fluids and contaminated materials. However, major scientific advancements including FDA-approved vaccines and monoclonal antibody therapies have significantly improved survival outcomes in recent years.
What Causes Ebola Virus Disease?
Ebola Virus Disease is caused by infection with one of several Ebola virus species. The virus is believed to originate in fruit bats, which act as natural reservoirs. Human infection may occur through contact with infected animals such as bats, monkeys, chimpanzees, or forest antelope.
Once introduced into humans, Ebola spreads through:
- Blood and body fluids of infected individuals
- Saliva, sweat, urine, vomit, semen, and breast milk
- Contaminated needles, bedding, clothing, or medical equipment
- Handling bodies of individuals who died from EVD
Unlike airborne diseases such as influenza or COVID-19, Ebola is not spread through casual air transmission.
Clinical Symptoms of Ebola Virus Disease
Symptoms of Ebola usually appear between 2 and 21 days after exposure, with an average incubation period of 8-10 days. The disease progresses rapidly and typically occurs in two clinical stages.
Early Symptoms of Ebola
Initial symptoms are often nonspecific and resemble common viral illnesses. These include:
- Sudden high fever
- Severe weakness and fatigue
- Muscle and joint pain
- Intense headache
- Sore throat
- Chills
Because these symptoms mimic malaria, typhoid, or influenza, early diagnosis can be challenging during outbreaks.
Advanced Symptoms and Severe Complications
As the infection progresses, patients may develop severe systemic complications such as:
- Persistent vomiting
- Severe diarrhea
- Abdominal pain
- Skin rash
- Liver and kidney dysfunction
- Internal bleeding
- External bleeding from gums, nose, or injection sites
- Blood in stools or vomit
In severe cases, Ebola triggers a massive inflammatory response leading to multi-organ failure, shock, and death.
Clinical studies from previous outbreaks showed mortality rates ranging from 25% to 90%, depending on healthcare access and outbreak response quality. According to the World Health Organization (WHO), the average fatality rate across outbreaks is approximately 50%.
How Ebola Virus Disease Is Diagnosed
Early and accurate diagnosis is essential to reduce transmission and improve survival. Healthcare providers use laboratory testing methods such as:
- Reverse transcription polymerase chain reaction (RT-PCR)
- Antigen detection tests
- Antibody-based blood tests
- Viral isolation in specialized laboratories
Patients suspected of Ebola infection must be isolated immediately to prevent spread.
FDA-Approved Ebola Vaccines
One of the most significant breakthroughs in global infectious disease control has been the development of effective Ebola vaccines.
Ervebo (rVSV-ZEBOV)
The FDA-approved vaccine Ervebo is highly effective against the Zaire ebolavirus species. It uses a recombinant vesicular stomatitis virus platform engineered to express Ebola virus proteins and stimulate immunity.
Clinical trials conducted during outbreaks in Guinea demonstrated that the vaccine provided substantial protection against Ebola infection. In ring vaccination strategies, vaccinated contacts and healthcare workers showed dramatically reduced infection rates.
Zabdeno and Mvabea Two-Dose Regimen
Another vaccine strategy includes the two-dose regimen of Zabdeno and Mvabea, which has been used in outbreak preparedness programs and specific high-risk populations.
Vaccination remains one of the most powerful tools for controlling Ebola outbreaks, especially among frontline healthcare workers and close contacts of infected individuals.
Ebola Prevention Strategies
Preventing Ebola transmission requires strict infection-control measures and public health awareness.
Key Prevention Guidelines
Health organizations including the Centers for Disease Control and Prevention (CDC) recommend:
- Avoiding direct contact with infected blood and bodily fluids
- Using personal protective equipment (PPE)
- Practicing proper hand hygiene
- Avoiding handling bodies of Ebola victims without protection
- Safe burial practices
- Disinfection of contaminated surfaces and medical equipment
- Isolation of infected individuals
Healthcare workers remain at particularly high risk and require specialized protective protocols during outbreaks.
Advanced Treatment Options for Ebola
There is currently no universal cure for Ebola Virus Disease, but supportive care and targeted therapies have dramatically improved patient survival.
Monoclonal Antibody Treatments
The FDA has approved two important monoclonal antibody therapies for Ebola treatment:
Inmazeb
Inmazeb is a combination of three monoclonal antibodies:
- Atoltivimab
- Maftivimab
- Odesivimab
These antibodies bind to the Ebola virus and prevent it from infecting healthy cells.
Ebanga (Ansuvimab)
Ebanga is another monoclonal antibody treatment designed to neutralize the Ebola virus effectively.
Clinical trials conducted during outbreaks in the Democratic Republic of Congo demonstrated significantly improved survival rates among patients receiving these therapies compared with older treatment methods.
Importance of Early Supportive Care
Supportive medical management plays a critical role in recovery. Evidence-based supportive care includes:
- Intravenous (IV) fluids
- Electrolyte replacement
- Oxygen therapy
- Blood pressure stabilization
- Treatment of secondary infections
- Nutritional support
Research indicates that patients receiving early aggressive supportive care have substantially higher survival rates than untreated individuals.
Long-Term Effects in Ebola Survivors
Many Ebola survivors experience long-term complications known as post-Ebola syndrome. Symptoms may include:
- Chronic fatigue
- Joint and muscle pain
- Vision problems
- Neurological complications
- Depression and anxiety
Some survivors may continue to carry viral particles in immune-protected sites such as the eyes or testes for months after recovery, emphasizing the importance of continued medical monitoring.
Global Health Response and Future Preparedness
The international response to Ebola has improved significantly over the past decade. Organizations such as the World Health Organization (WHO), CDC, and global research networks continue to strengthen surveillance systems, outbreak preparedness, and vaccine distribution strategies.
Rapid diagnostic testing, vaccination campaigns, and monoclonal antibody therapies have transformed Ebola from an almost universally fatal disease into a more manageable infection when treated early.
However, continued vigilance remains essential, particularly in regions with limited healthcare infrastructure and ongoing zoonotic exposure risks.
The Bottom Line
Ebola Virus Disease remains one of the most severe viral infections known to medicine. Its rapid progression, high fatality rate, and potential for outbreaks make it a major global health concern. Fortunately, advances in vaccines, monoclonal antibody therapies, and supportive care have significantly improved survival outcomes.
Public awareness, early diagnosis, strict infection-control practices, and rapid access to medical treatment are crucial for controlling future outbreaks. Continued global collaboration and investment in infectious disease preparedness will remain vital in reducing the impact of Ebola worldwide.
- Written By: Shabina Khan (Clinical Pharmacist)
- Reviewed By: Dr Abdul Qayyoom (MBBS, MD Scholar)